跳至主要内容
临床试验/NCT07276009
NCT07276009尚未招募不适用

The Effect of Multi-strain Probiotic Formulation on Gastrointestinal Symptoms, Quality of Life and Mental Health in Patients With Functional Dyspepsia: a Randomized Dietary Trial

Nordic Biotic Sp. z o.o.0 个研究点目标入组 60 人开始时间: 2026年1月5日最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
入组人数
60
主要终点
Change in Gastrointestinal Symptom Rating Scale

研究概览

简要总结

The goal of this clinical trial is to learn whether a multi-strain probiotic can reduce digestive symptoms and improve quality of life in adults with functional dyspepsia. The main questions it aims to answer are:

  • Does the probiotic reduce symptoms such as fullness after meals, bloating, stomach discomfort, and early satiation?
  • Does the probiotic improve emotional well-being, including stress, anxiety, and mood? Researchers will compare the probiotic to a placebo (a look-alike capsule with no active ingredients) to see if the probiotic truly helps adults with functional dyspepsia.

Participants will:

  • Take one capsule of the probiotic or placebo once daily before meals for 60 days
  • Complete questionnaires about their digestive symptoms at the start, 1 month, and 2 months
  • Complete surveys on stress, anxiety, depression, and quality of life at the start and 2 months
  • Attend scheduled study visits for checkups and assessments

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age 18-65 years
  • Diagnosis of Functional Dyspepsia based on Rome IV criteria, with symptoms present for at least 3 months, and symptom onset at least 6 months before diagnosis, including:
  • Postprandial fullness
  • Early satiation
  • Epigastric pain or burning
  • (with no evidence of structural disease explaining symptoms)
  • Moderate to severe symptom severity at baseline, as defined by a validated scale (e.g., NDI or global symptom score)
  • Normal upper GI endoscopy within the last 12 months (or at screening), excluding structural disease (e.g., peptic ulcer, malignancy)
  • Negative for H. pylori (either previously treated successfully or tested negative within study screening)
  • Ability and willingness to provide informed consent and comply with study procedures
  • Stable medication use, if any, for at least 4 weeks before screening (e.g., PPIs, antidepressants, laxatives)

排除标准

  • Evidence of structural GI disease (e.g., peptic ulcer, gastric cancer, celiac disease) on recent or screening endoscopy
  • History of gastrointestinal surgery affecting stomach or small intestine (except appendectomy or cholecystectomy)
  • Positive test for H. pylori during screening (or untreated known infection)
  • Current or recent use (within 4 weeks) of antibiotics, pre-, pro- or postbiotics, unless part of study protocol
  • Use of medications affecting GI motility (e.g., prokinetics, opioids, anticholinergics) within 2-4 weeks before enrollment
  • Overlap with other functional GI disorders (except IBS) if they are the dominant complaint, unless your protocol allows overlap
  • Clinically significant psychiatric illness (e.g., major depression, schizophrenia) that may interfere with symptom reporting or adherence
  • Severe systemic or metabolic disease (e.g., uncontrolled diabetes, renal or hepatic failure)
  • Pregnancy or lactation, or intention to become pregnant during the study period
  • Participation in another clinical trial within the past 3 months
  • Known allergy or intolerance to study product components

结局指标

主要结局

Change in Gastrointestinal Symptom Rating Scale

时间窗: 30 and 60 days

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

相似试验